As part of this reorganization, Rentschler will withdraw from the field of cell and gene therapy, cease operations at its Stevenage, UK, site and focus more on biologics.

“The cell and gene therapy market has experienced slower-than-expected growth, with demand across the industry not meeting our expectations. Following a comprehensive strategic review, we are focusing our efforts on areas where we see the greatest demand and potential to create value sustainably. Biologics remain central to our operations, while we continue to evaluate other potential modalities, leveraging our expertise and outstanding track record of delivering the exceptional quality and service our clients rely on,” said Benedikt von Braunmühl, CEO of Rentschler.

In recent years, Rentschler has made significant investments to further strengthen its global capabilities and support long-term growth. In October 2024, the company announced its largest single investment to date at its headquarters in Laupheim, Germany, to enhance production efficiency and upgrade the site’s capabilities. In July of last year, the new, state-of-the-art production line in Milford, MA in the USA, with four new 2,000-litre single-use bioreactors, went into full operation.